Sanofi-Aventis

:

Genzyme

Dealogic Deal #  :

683219

Data as of :

8/30/2010

Target

Acquiror

Dates & Values

Genzyme

Sanofi-Aventis

Target:

100

% stake

Buying:

100

% stake

Rumored

6th May 2010

Deal Value $m

18,480.4

NS

GENZ

255

m shares outstanding

Public (Listed)

Announced

29th Aug 2010

Value ex Debt $m

18,200.5

United States

France

Healthcare

Healthcare

Expected

4Q 2010

Consideration

Goldman Sachs | Advisor

JPMorgan | Advisor

Completed

-

Credit Suisse | Advisor

Evercore Partners | Advisor

Ropes & Gray | Attorney

Weil Gotshal &Manges | Attorney

Withdrawn

-

Termination Fee, Target $m

tbd

Termination Fee, Acquiror $m

tbd

Financials

30th Jun 2010

Balance Sheet

Debt/Equity:

0.5

Timeline Events

Premiums & Multiples

Initial Offer

$69.00

Current Offer

$69.00

Income Statement

Cash Flows

Operations $m

884

Profitability

Profit Margin

-4%

Return on Equity

-1%

League Table Impact

Sector Trend

2010 YTD Announced Global M&A by Deal Value, $bn

Monthly Announced Global M&A, $bn:

Healthcare

1

Goldman Sachs

391.2

2

JPMorgan

344.7

3

Credit Suisse

303.8

4

Morgan Stanley

303.5

5

BOA Merrill Lynch

265.1

6

Barclays Capital

213.3

7

Citi

207.4

8

Deutsche Bank

205.9

9

Lazard

193.7

10

UBS

175.1

19

Evercore

61.0

© 2010 Dealogic.  All rights reserved.